Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 181,230 shares of the company's stock after acquiring an additional 9,416 shares during the period. Rhumbline Advisers owned 0.14% of Vaxcyte worth $6,843,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte during the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC lifted its stake in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares in the last quarter. National Bank of Canada FI acquired a new stake in shares of Vaxcyte in the fourth quarter valued at $41,000. Blue Trust Inc. grew its stake in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after buying an additional 371 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after buying an additional 1,071 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Trading Down 2.8%

PCVX stock traded down $0.98 during trading on Thursday, hitting $34.46. 1,205,768 shares of the company's stock were exchanged, compared to its average volume of 1,441,016. The business has a 50-day moving average price of $32.54 and a two-hundred day moving average price of $64.03. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of -7.49 and a beta of 1.20. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period last year, the firm posted ($0.85) EPS. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

PCVX has been the topic of several recent research reports. The Goldman Sachs Group cut their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Cantor Fitzgerald started coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating for the company. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Finally, Guggenheim reiterated a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.